Polyethylene glycol 3350

MiraLAX is an FDA-approved OTC drug under NDA022015 for occasional constipation. It generally produces a bowel movement in 1–3 days. Its adult/older-adolescent self-treatment label does not establish a routine pediatric or chronic-disease schedule.

The ACG public summary of the 2023 joint AGA-ACG guideline reports a strong recommendation for PEG in adult chronic idiopathic constipation. Longer clinician-directed treatment differs from the OTC seven-day self-treatment limit. This focused profile does not supply an unsourced pediatric disimpaction or universal long-term titration regimen.

The selected PEG3350/electrolyte four-liter prescription product is approved under ANDA090231 for bowel cleansing before colonoscopy or barium-enema X-ray examination in adults. It is a separate high-volume combination, not a larger scoop of MiraLAX or an interchangeable sports-drink mixture. Other bowel-preparation formulations require their own label and procedural plan.

For age 17 years and older, take 17 g orally once daily: fill the marked cap to its white dose line or use one 17 g packet. Dissolve in 4–8 ounces of a beverage at cold, room or hot temperature, stir until fully dissolved with no clumps, and drink. Do not take more than directed or continue beyond seven days without medical advice. Age 16 and younger: ask a doctor; no numerical pediatric dose appears in this OTC label.

Reconstitute the supplied 236 g PEG/electrolyte jug with drinking water to the 4-liter line; do not add unapproved ingredients. Its labeled adult evening-before regimen drinks 8 ounces every 10 minutes until the contents are consumed or effluent is clear. The supervised nasogastric label rate is 20–30 mL/min. Follow the procedure team’s complete food, clear-fluid and fasting plan; label permits clear fluids until two hours before colonoscopy and prohibits solid food within two hours before starting. These instructions do not establish a universal split-dose schedule for every PEG product.

Do not combine either reviewed PEG product with starch-based thickeners used for dysphagia: PEG can thin the liquid and undermine swallowing safety. A clinician must plan an appropriate alternative administration approach rather than simply add more thickener. Never swallow undissolved powder.

Correct fluid/electrolyte abnormalities before preparation and maintain clinician-directed hydration. Severe bloating, distention or pain requires slowing or temporarily stopping and assessment. Prescription preparation can impair oral-drug absorption: do not take oral medicines within one hour before starting or during administration, as clearly stated in §2.1 and the Medication Guide. The contradictory wording in §7.2 is recorded as a source error, not propagated.

Do not use MiraLAX with PEG allergy; kidney disease is an OTC doctor-supervision restriction rather than a published renal-dose algorithm. The selected prescription preparation formally contraindicates GI obstruction, perforation, ileus, gastric retention, toxic colitis/toxic megacolon and component hypersensitivity. Inform the clinician about obstruction symptoms before using any laxative.

The reviewed MiraLAX Drug Facts and selected prescription PEG/electrolyte full label have no formal boxed warning. Serious hypersensitivity, fluid/electrolyte complications and aspiration warnings remain clinically important.

Constipation therapy can cause bloating, nausea, cramping, gas and diarrhea. Prescription bowel cleansing commonly causes nausea, fullness/bloating and cramps; uncommon serious reports include electrolyte-related seizures/arrhythmias, kidney injury, anaphylaxis, aspiration and GI injury. Spontaneous reports do not establish precise frequencies or causal certainty for every event.

The current OTC label says to ask a doctor or pharmacist before use when taking a prescription medicine. It does not supply a mandatory universal two-hour separation, quantified CYP interaction or dose reduction for all drugs. Verify companion-drug needs and the actual constipation plan.

Do not take oral medicines within one hour before starting or during the selected preparation; manage time-critical drugs with the procedural team. Avoid other laxatives, especially stimulant agents. Diuretics, ACE inhibitors, ARBs, NSAIDs and drugs that raise electrolyte-related seizure/arrhythmia risk need individualized review, hydration and possible laboratory assessment; this label does not require automatically withholding every such medicine.

The prohibition on starch-based swallowing thickeners applies to the reviewed constipation powder and prescription preparation. This is a physical viscosity/aspiration issue, not permission to change a dysphagia diet independently.

OTC numerical instructions start at age 17; age 16 and younger requires a doctor. The selected bowel-preparation product is adult-labeled, with pediatric safety/effectiveness not established. Older patients need assessment of dehydration, organ function, swallowing and medication risks rather than an invented age-only reduced scoop.

Use prescription preparation cautiously with impaired renal function or renal-risk medicines; consider baseline and postprocedure electrolytes, creatinine and BUN, and individualize hydration, especially with heart failure. The OTC kidney-disease warning also requires clinician supervision. Neither reviewed product supplies a creatinine-clearance dosing table or a hepatic-only numerical adjustment; absence of a table is not proof that monitoring is unnecessary.

MiraLAX directs pregnant or breastfeeding patients to a health professional before use. The selected prescription preparation lacks adequate pregnancy and milk-exposure data and calls for cautious clinically needed use. Poor absorption does not establish zero fetal/infant risk or make an unsupervised preparation appropriate.

PEG3350 acts osmotically, retaining intestinal water to soften stool and facilitate passage. High-volume PEG/electrolyte preparations produce watery evacuation for cleansing. Their electrolyte composition and prescribed preparation volume distinguish them from single-ingredient constipation doses.

The selected prescription label states that oral PEG3350 is poorly absorbed, while PK of that exact combination was not assessed. No precise systemic half-life, complete absence of absorption or universal renal-clearance algorithm is asserted. Current MiraLAX onset is usually 1–3 days; its label takes precedence over the older NLM page’s 2–4-day wording.

Track response, stool consistency, abdominal symptoms and duration. Seek advice for alarm symptoms and before continuing beyond seven days. Measure the 17 g dose accurately and dissolve completely; avoid starch-based thickeners. Keep medicines out of children’s reach and discuss pregnancy, kidney disease and other prescriptions.

Assess hydration/electrolytes and renal, cardiac, seizure or aspiration risk before preparation. Consider renal/electrolyte tests in higher-risk patients and ECGs when serious arrhythmia risk warrants. Follow the procedural team’s fasting/medication plan; do not replace a prescribed preparation with an improvised powder/beverage recipe.

Breathing difficulty, throat swelling or collapse needs emergency care. Rectal bleeding, worsening abdominal pain, persistent vomiting or troublesome diarrhea needs prompt assessment. Significant vomiting/dehydration during bowel preparation may require laboratory testing and treatment; persistent need for a laxative also warrants evaluation.

Selected Bayer MiraLAX is unflavored PEG3350 powder with 17 g per cap-line dose or packet and no inactive ingredients in Drug Facts. Retain the original labeled bottle/packet and verify the actual NDC/package; powder appearance alone cannot authenticate a product.

MiraLAX is single-ingredient oral powder; reviewed packets contain 17 g and bottles include 510 g/30-dose and 578 g/34-dose sizes. Selected Novel prescription preparation is a 4-liter jug containing 236 g PEG3350 plus 22.74 g sodium sulfate, 6.74 g sodium bicarbonate, 5.86 g sodium chloride and 2.97 g potassium chloride; NDC 40032-090-19. This is not an OTC 17 g packet formulation.

MiraLAX: 20–25°C; do not use a bottle with compromised foil seal. Selected prescription dry jug: 15–30°C sealed; after reconstitution refrigerate 2–8°C, do not freeze, use within 48 hours and discard remaining solution. Keep each product’s own mixing and storage instructions with it.